EP0871643A4 - Anti-viral guanosine-rich oligonucleotides - Google Patents

Anti-viral guanosine-rich oligonucleotides

Info

Publication number: EP0871643A4
Authority: EP; European Patent Office
Prior art keywords: rich oligonucleotides; guanosine; viral; viral guanosine; oligonucleotides
Prior art date: 1995-07-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP96930490A

Other languages

German (de)

French (fr)

Other versions

EP0871643A1 (en

Inventor

Robert F Rando

Susan Fennewald

Joseph G Zendegui

Joshua O Ojwang

Michael E Hogan

Yves Pommier

Abhijit Mazumder

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aronex Pharmaceuticals Inc

Original Assignee

Aronex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-19

Filing date

1996-07-17

Publication date

2000-12-06

1994-04-25 Priority claimed from US08/535,168 external-priority patent/US6184369B1/en

1996-07-17 Application filed by Aronex Pharmaceuticals Inc filed Critical Aronex Pharmaceuticals Inc

1998-10-21 Publication of EP0871643A1 publication Critical patent/EP0871643A1/en

2000-12-06 Publication of EP0871643A4 publication Critical patent/EP0871643A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP96930490A 1995-07-19 1996-07-17 Anti-viral guanosine-rich oligonucleotides Withdrawn EP0871643A4 (en)

Applications Claiming Priority (13)

Application Number	Priority Date	Filing Date	Title
US601505		1984-04-18
US08/535,168 US6184369B1 (en)	1993-04-23	1994-04-25	Anti-viral guanosine-rich oligonucleotides
US150595P	1995-07-19	1995-07-19
US1368896P	1996-03-19	1996-03-19
US61368		1996-03-19
US1400796P	1996-03-25	1996-03-25
US64007		1996-03-25
US1571496P	1996-04-17	1996-04-17
US15714		1996-04-17
US1627196P	1996-04-23	1996-04-23
PCT/US1996/011786 WO1997003997A1 (en)	1995-07-19	1996-07-17	Anti-viral guanosine-rich oligonucleotides
US5351		1998-01-09
US16271		2001-11-02

Publications (2)

Publication Number	Publication Date
EP0871643A1 EP0871643A1 (en)	1998-10-21
EP0871643A4 true EP0871643A4 (en)	2000-12-06

Family

ID=27555390

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP96930490A Withdrawn EP0871643A4 (en)	1995-07-19	1996-07-17	Anti-viral guanosine-rich oligonucleotides

Country Status (4)

Country	Link
EP (1)	EP0871643A4 (en)
AU (1)	AU725936B2 (en)
CA (1)	CA2227867A1 (en)
WO (1)	WO1997003997A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6288042B1 (en)	1993-04-23	2001-09-11	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich tetrad forming oligonucleotides
US5912332A (en) *	1996-07-26	1999-06-15	Hybridon, Inc.	Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
SI20117A (en) *	1996-12-27	2000-06-30	Icn Pharmaceuticals, Inc.	G-rich oligo aptamers and methods of modulating an immune response
AU6262598A (en) *	1997-02-04	1998-08-25	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich tetrad forming oligonucleotides
AU2006302022A1 (en) *	2005-10-06	2007-04-19	University Of Delaware	G-rich polynucleotides for the treatment of Huntington's Disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994008053A1 (en) *	1992-09-29	1994-04-14	Isis Pharmaceuticals, Inc.	Oligonucleotides having a conserved g4 core sequence
WO1994025037A1 (en) *	1993-04-23	1994-11-10	Triplex Pharmaceutical Corporation	Anti-viral guanosine-rich oligonucleotides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3687808A (en) *	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US4388306A (en) *	1980-06-04	1983-06-14	Merck & Co., Inc.	Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates
FR2567892B1 (en) *	1984-07-19	1989-02-17	Centre Nat Rech Scient	NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
GB8717430D0 (en) *	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5176996A (en) *	1988-12-20	1993-01-05	Baylor College Of Medicine	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5397702A (en) *	1989-03-06	1995-03-14	The Regents Of The University Of California	Assay for and treatment of autoimmune diseases
US5075217A (en) *	1989-04-21	1991-12-24	Marshfield Clinic	Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5173426A (en) *	1989-10-06	1992-12-22	Yale University	DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
DE4216134A1 (en) *	1991-06-20	1992-12-24	Europ Lab Molekularbiolog	SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES

1996
- 1996-07-17 AU AU69506/96A patent/AU725936B2/en not_active Ceased
- 1996-07-17 CA CA002227867A patent/CA2227867A1/en not_active Abandoned
- 1996-07-17 EP EP96930490A patent/EP0871643A4/en not_active Withdrawn
- 1996-07-17 WO PCT/US1996/011786 patent/WO1997003997A1/en not_active Application Discontinuation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994008053A1 (en) *	1992-09-29	1994-04-14	Isis Pharmaceuticals, Inc.	Oligonucleotides having a conserved g4 core sequence
WO1994025037A1 (en) *	1993-04-23	1994-11-10	Triplex Pharmaceutical Corporation	Anti-viral guanosine-rich oligonucleotides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BISHOP JEFFREY S ET AL: "Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5698 - 5703, XP002148821, ISSN: 0021-9258 *
FUJIHASHI T ET AL: "ANTIVIRAL ACTION OF OLIGODEOXYGUANYLIC ACIDS AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE I", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, no. 4, April 1995 (1995-04-01), pages 461 - 471, XP002068239, ISSN: 0889-2229 *
MAZUMDER ABHIJIT ET AL: "Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures.", BIOCHEMISTRY, vol. 35, no. 43, 29 October 1996 (1996-10-29), pages 13762 - 13771, XP002148822, ISSN: 0006-2960 *
MOUSCADET JEAN-FRANCOIS ET AL: "Triplex-mediated inhibition of HIV DNA integration in vitro.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 34, 1994, pages 21635 - 21638, XP002148820, ISSN: 0021-9258 *
OJWANG JOSHUA O ET AL: "T30177, an oligonucleotide stabilized by an intramolecular guanosine, Octet, is a potent inhibitor of laboratory strains, and clinical isolates of human immunodeficiency virus type 1.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 39, no. 11, November 1995 (1995-11-01), pages 2426 - 2435, XP000946679, ISSN: 0066-4804 *
RANDO R F ET AL: "SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ACTIVITY IN VITRO BY OLIGONUCLEOTIDES WHICH FORM INTRAMOLECULAR TETRADS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 4, 27 January 1995 (1995-01-27), pages 1754 - 1760, XP002068457, ISSN: 0021-9258 *
See also references of WO9703997A1 *

Also Published As

Publication number	Publication date
EP0871643A1 (en)	1998-10-21
AU6950696A (en)	1997-02-18
WO1997003997A1 (en)	1997-02-06
AU725936B2 (en)	2000-10-26
CA2227867A1 (en)	1997-02-06

Publication	Publication Date	Title
EP0699071A4 (en)	1998-12-23	Anti-viral guanosine-rich oligonucleotides
IL122377A0 (en)	1998-06-15	Anti-viral compounds
IL118545A0 (en)	1996-10-16	Anti-viral compounds
DE59602888D1 (en)	1999-09-30	Breitstreckaggregat
EP0871643A4 (en)	2000-12-06	Anti-viral guanosine-rich oligonucleotides
DE59602030D1 (en)	1999-07-01	Zellige polyurethan-elastomere
DE59602283D1 (en)	1999-07-29	Inchbremseinrichtung
GB9518539D0 (en)	1995-11-08	Complex
DE59505396D1 (en)	1999-04-22	Handhobelmaschine
EP1021674A4 (en)	2000-07-26	Formed ragglestick
AP9600802A0 (en)	1996-04-30	Libricant
DE59600830D1 (en)	1998-12-24	Breitstrahldüse
GB9515308D0 (en)	1995-10-11	Complex
GB2307038B (en)	1999-07-21	Baffle
GB9512815D0 (en)	1995-08-23	Anti-viral compounds
AU1105P (en)	1998-09-23	DALESE Metrosideros excelsus
HU9500211V0 (en)	1995-09-28	Small shording section
PL103537U1 (en)	1997-04-14	Shape
IL113924A0 (en)	1995-08-31	Mechanotherapy complex
ZA969476B (en)	1997-06-02	Complex
ZA967806B (en)	1997-04-07	Forming solutions
GB9500391D0 (en)	1995-03-01	Forming solutions
AU124982S (en)	1995-10-26	Snow - bike
AU125614S (en)	1996-01-15	Billycart
AU125678S (en)	1996-01-22	Sandboard

Legal Events

Date	Code	Title	Description
1998-09-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1998-10-21	17P	Request for examination filed	Effective date: 19980216
1998-10-21	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2000-12-06	A4	Supplementary search report drawn up and despatched	Effective date: 20001018
2000-12-06	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-09-24	17Q	First examination report despatched	Effective date: 20030811
2005-09-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2005-11-16	18D	Application deemed to be withdrawn	Effective date: 20050508